Ildstad Suzanne
Director at Talaris Therapeutics, Inc.
- Sold, on record
- $2.7M
- Dollars the filings state
- Form 4 sales
- 13
- Latest Jun 14, 2023
- Form 144 notices
- 2
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Talaris Therapeutics, Inc.Director
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Talaris Therapeutics, Inc.UnusualApr 20, 2023 2023
Sold 68,743 shares at $2.28 ($156k)
Ildstad Suzanne, Director
10b5-1 planSold 2.4% of holdings ($6.6M position)2.8M shares left10.1x usual sizeFiling
- 2 Form 144 notice Talaris Therapeutics, Inc.NoticeApr 21, 2023 +1 day
Filed to sell 10,051 shares ($24k)
Ildstad Suzanne, Officer
10b5-1 plan1.2x usual sizeFiling
- 3 Form 4 sale Talaris Therapeutics, Inc.RoutineApr 21, 2023 same day
Sold 15,004 shares at $2.35 ($35k)
Ildstad Suzanne, Director
10b5-1 planSold 0.5% of holdings ($6.7M position)2.8M shares left1.7x usual sizeFollows a Form 144Filing
- 4 Form 144 notice Talaris Therapeutics, Inc.NoticeJun 1, 2023 +41 days
Filed to sell 250,000 shares ($663k)
Ildstad Suzanne, Director
10b5-1 plan24x usual sizeFiling
- 5 Form 4 sale Talaris Therapeutics, Inc.UnusualJun 2, 2023 +1 day
Sold 31,531 shares at $2.53 ($80k)
Ildstad Suzanne, Director
10b5-1 planSold 1.1% of holdings ($7.1M position)2.8M shares left3x usual sizeFollows a Form 144Filing
- 6 Form 4 sale Talaris Therapeutics, Inc.RoutineJun 6, 2023 +4 days
Sold 33,390 shares at $2.53 ($84k)
Ildstad Suzanne, Director
10b5-1 planSold 1.2% of holdings ($7.1M position)2.8M shares left2.6x usual sizeFollows a Form 144Filing
- 7 Form 4 sale Talaris Therapeutics, Inc.UnusualJun 9, 2023 +3 days
Sold 141,062 shares at $2.43 ($343k)
Ildstad Suzanne, Director
10b5-1 planSold 3.6% of holdings ($9.6M position)3.8M shares left9.4x usual sizeFollows a Form 144Filing
- 8 Form 4 sale Talaris Therapeutics, Inc.RoutineJun 14, 2023 +5 days
Sold 44,020 shares at $2.55 ($112k)
Ildstad Suzanne, Director
10b5-1 planSold 1.2% of holdings ($9.7M position)3.8M shares left1.9x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (15)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2023 | Jun 14, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 44,020 | $112k | 1.2% | Routine | SEC |
| Jun 9, 2023 | Jun 9, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 141,062 | $343k | 3.6% | Unusual | SEC |
| Jun 6, 2023 | Jun 7, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 33,390 | $84k | 1.2% | Routine | SEC |
| Jun 2, 2023 | Jun 5, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 31,531 | $80k | 1.1% | Unusual | SEC |
| Jun 1, 2023 | Jun 1, 2023 | Talaris Therapeutics, Inc. | Director | Form 144 notice | 250,000 | $663k | Notice | SEC | |
| Apr 21, 2023 | Apr 25, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 15,004 | $35k | 0.5% | Routine | SEC |
| Apr 21, 2023 | Apr 21, 2023 | Talaris Therapeutics, Inc. | Officer | Form 144 notice | 10,051 | $24k | Notice | SEC | |
| Apr 20, 2023 | Apr 21, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 68,743 | $156k | 2.4% | Unusual | SEC |
| Apr 18, 2023 | Apr 19, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 148,982 | $319k | 4.9% | Unusual | SEC |
| Mar 17, 2023 | Mar 20, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 10,436 | $21k | 0.3% | No plan | SEC |
| Mar 3, 2023 | Mar 7, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 6,806 | $14k | 0.2% | Plan not stated | SEC |
| Mar 1, 2023 | Mar 2, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 29 | $59 | 0.0% | Plan not stated | SEC |
| Feb 21, 2023 | Feb 23, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 3,500 | $7k | 0.1% | Plan not stated | SEC |
| Feb 17, 2023 | Feb 21, 2023 | Talaris Therapeutics, Inc. | Director | Form 4 sale | 6,551 | $13k | 0.2% | Plan not stated | SEC |
| Aug 22, 2022 | Aug 23, 2022 | Talaris Therapeutics, Inc. | Chief Scientific Officer | Form 4 sale | 525,000 | $1.5M | 14.6% | Plan not stated | SEC |